
Simplicardiac S.A.
Other research and experimental development on natural sciences and engineering
Overview
Simplicardiac is dedicated to automated arterial access site management, providing solutions that enhance outcomes and reduce costs in endovascular procedures. The company offers the Simpliactive bots and platform, which automate access site management by mimicking manual compression and controlling bleeding throughout the healing process. Their technology is designed to address complications related to access sites in interventional cardiovascular procedures.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2024 – the filing deadline has passed. 3 of 3 financial statements were filed late (the longest delay 284 days for 2021). All were audited by a statutory auditor.
- 2024not filed
- 202330/01/2025
- 202212/12/2023
- 202125/04/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2023.
Results vs industry
Industry
Offer
- Automatic arterial access closure device
- Vascular access site monitoring system
- Vascular access site management
- Bleeding control technology
- Systems for endovascular procedures
Websites
- simplicardiac.comHome Page
Job offers
The company lists 2 job openings on its own careers page: simplicardiac.com/careers.
Authorized Representatives
Manner of representation
Each member of the management board is entitled to perform legal acts and make declarations on behalf of the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Cardiobotics sp. z o.o. | 1,593.73 USD | 100% |
Bank accounts
Was a VAT taxpayer from 2013-03-13 to 2025-09-09.
Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 2, 2020 | Aid for SMEs for innovation support | $92,585$92,585 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-08-01 | Legal protection of industrial property for the invention “Medical device for compressing a blood vessel” | $94,032$94,032 | Operational Programme Smart Growth |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Quantum Innovations sp. z o.o. | $167,489.61 | quantuminnovations.pl | ||
| Selkod sp. z o.o. | $115,034.31 | selkod.com.pl | ||
| OREI Health sp. z o.o. | $86,777.19 | oreihealth.com | ||
| Spark Group sp. z o.o. | $75,379.54 | sparkgroup.com.pl | ||
| Wytwórnia Sprzętu Sanitarnego Sanmed sp. z o.o. | $52,702.04 | sanmed.pl | ||
| Infinity Flow sp. z o.o. | $50,226.02 | infinityflow.pl | ||
| Ogarit sp. z o.o. | $48,793.46 | ogarit.pl | ||
| Medinice B+R sp. z o.o. | $43,773.58 | medinice.pl | ||
| OPTI G sp. z o.o. | $34,289.31 | optig.pl | ||
| Biotreat Vascular sp. z o.o. | $20,270.13 | biotreatvascular.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-12-12 | Share capital increase (293,291.00 PLN → 891,231.00 PLN) | |
| 2024-06-24 | Share capital increase (282,691.00 PLN → 293,291.00 PLN) | |
| 2024-04-26 | Share capital increase (200,800.00 PLN → 282,691.00 PLN) | |
| 2021-12-13 | Entered in the register |
FAQ
Last updated: 2026-04-01